Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.
about
Pegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for peripheral stem cell mobilizationIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersAntibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationPrimary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationPegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for patients after hematopoietic stem cell transplantationPegylated granulocyte colony stimulating factor versus non-pegylated granulocyte colony stimulating factor for peripheral stem cell mobilizationQ24235340Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersGranulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyAntibiotics plus colony stimulating factors versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationProphylactic antibiotics and G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyBiosimilars in the management of neutropenia: focus on filgrastimGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectivePredicting neutropenia risk in patients with cancer using electronic data.Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.Impact of acute hematological toxicity on treatment interruptions during cranio-spinal irradiation in medulloblastoma: a tertiary care institute experience.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysisPharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialHematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Food-borne bacteremic illnesses in febrile neutropenic children.Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.A way forward on the medically appropriate use of white cell growth factorsEffects of granulocyte-colony stimulating factor and the expression of its receptor on various malignant cellsFebrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis.A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and DocetaxelCanadian supportive care recommendations for the management of neutropenia in patients with cancer.Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model.Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology GroupM-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation.Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.
P2860
Q24186269-E385E940-05A6-4030-B39F-AD7D5E044DD5Q24186274-8F464EBB-3B8D-4B0D-A6CE-51781DCA0E7BQ24186282-BDD10CAA-55DB-4BBD-8E99-6BF4C0881EDFQ24198118-3FF38A5F-060B-4418-8B71-0F251EE00FB0Q24200225-C931FC57-A876-40AF-A499-078983F3AD27Q24201099-71AD8367-FCA6-4F4B-90BE-B63E2B7A0B54Q24201219-F272F830-AB0B-4E1C-8B6D-2756A7D6D360Q24235340-D427E98F-577E-4AB2-910D-911C883BB7ABQ24235345-B396BDF9-5D7C-4FFA-9A75-D2559223D78AQ24236448-85A7F2FD-5586-434E-9539-4715E67FF952Q24240753-FC988DBA-7B0D-4B93-819C-6BA8A60AC028Q24241475-42C4E11F-23B6-4C34-9192-DF53138C5652Q24241680-B52A67F4-ABB4-4A7E-84A3-C3B26B5C3A1AQ24241689-161B72EC-B3B0-4FA2-8BC2-00B2FCE19E86Q24243543-4BC760CC-C56B-4E25-9707-0D6D0FF61C85Q26764906-754A761F-DD22-43E7-91C6-EAC066407F27Q28388806-F7DBC211-99BA-4BB2-B92A-08624B0418FDQ31131362-02E1F93F-8024-43A2-8E6F-D620616A4C96Q33383573-97542F24-29C1-4097-94C6-CBE1FD3A3F98Q33442381-5EA83366-ADD2-479F-B6FE-9B616859B808Q33756369-856ADEEB-48EE-4BE0-8EC4-E6804DDCCE33Q33789362-C96D7CDA-D0C9-4052-915A-92E6727C9219Q34013208-D4E229B8-8760-4407-9D6D-293FEA2B918EQ34620664-F33C55C5-DB45-4097-A346-A580885B35DCQ34632953-D39C4CEF-76F9-4101-8C98-539640557BCDQ34678894-DB164F45-B050-4E8F-9F80-E70FBBBFBDEDQ34982532-8A67E63A-C7C0-4FFB-9647-9534AA3B1DCEQ35044368-3FE2AAB8-DC4B-4921-9CC0-39C33451CC56Q35615338-03B6F120-1FE5-4E1F-859F-4A0E3DE6C2CFQ36007020-28C865A9-DF79-4FAC-A564-7D878EA75DA0Q36053792-08C549C2-8B8A-4037-819C-5DD68F8C1E32Q36058245-1ED86585-ADF5-497C-9EBE-2962F72CD8E3Q36297673-CD0DC154-EB9C-4266-B941-22E3CD5E98ECQ36416237-4581704C-5DCE-4B5B-A9A6-126A06017B9BQ36452230-A5A1A503-5066-4E78-9541-E6E7E5398C3AQ36485208-1A0CF606-6B46-4E7B-8A5C-75C0259E1F17Q36595328-29792B59-5511-4D4A-A994-C3E80AFDDF09Q36814599-E239AFCD-C54F-423F-9A1A-1CCB88841CE2Q37346652-773BFDFD-39DC-4FAC-B712-06B9D26FD2EEQ37387000-41B17176-73AB-4F8C-872F-30BE91FEA428
P2860
Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@ast
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@en
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@nl
type
label
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@ast
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@en
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@nl
prefLabel
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@ast
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@en
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@nl
P2093
P1476
Meta-analysis: effect of proph ...... ity and outcomes of infection.
@en
P2093
George A Tomlinson
Joseph Beyene
Lillian Sung
Paul C Nathan
Shabbir M H Alibhai
P304
P356
10.7326/0003-4819-147-6-200709180-00010
P407
P577
2007-09-01T00:00:00Z